Altimmune announces fda clearance of pemvidutide (alt-801) ind for obesity

Enrollment in 48-week phase 2 clinical trial expected to begin in q1 2022 enrollment in 48-week phase 2 clinical trial expected to begin in q1 2022
ALT Ratings Summary
ALT Quant Ranking